Biotricity公司作为一家专注于生物识别数据监测的医疗技术企业，公布了其截至2025年3月31日的季度财务报告。 公司在这一季度实现了调整后EBITDA的正值，达438,260美元，这标志着从上一财年同期的负256万美元大幅逆转。 这一显著进步凸显了运营效率的持续提升。 归属于普通股股东的净亏损约为202万美元，较去年同期440万美元的亏损明显收窄。 这种趋势反映了财务绩效的积极向好。 Biotricity致力于为医疗、保健和消费市场提供创新的远程监测解决方案，尤其在生活方式和慢性疾病的诊断及后诊断领域。 公司正专注于在已有报销机制的商业模式中应用创新，以有效降低运营风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.